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APV by acetylcholine (10 microglkgimin) injection into mAA. The endothelium-indepen- 
dent vascular function (EIDVF) was determmed as a ratio of basal to peak of APV by 
nitroglycerin (10 microglkglmm) injection Into mAA. Simultaneously, the plasma isopros- 
tame FPalpha-Ill was measured by ELISA kit (Oxford Biomedical). Results: The infusion 
of isoprostane F2alpha-Ill significantly attenuate EDVF in CH rabbits (1.8 iO.3 vs. 2.3 
kO.1; p<O.Ol). The treatment by ramatroban can improve the EDVF in CH rabbits (3.8 
i0.2 vs. 2.3 +O.l; p<O.Ol). There was no significant difference in the EIDVF among the 
four groups. The plasma isoprostane FPalpha-Ill levels in CH or CH + IP rabbits was sig- 
nificant higher than NL rabbits (488 244. 858 *59 vs. 256 *17 ng/ml,both ~~0.01). Con- 
clusion: This study suggested that isoprostane FPalpha-Ill synthesis induced by 
experimental hypercholesterolemia may be due to impaired endothelial function in rab- 
bits. This effect may be due to TXAP receptor stimulation. 
1155-150 Comparison of Effect of Thiazolidinediones on 
Atherosclerosis in Apolipoprotein E-Deficient Mice 
Masaaki Mivata Qi Gong, Sadatoshl Biro, Hideyuki Eta, Koii Orihara, Tow Obata. 
Shinichi Minagoe. Chuwa Tei, Kagoshima University, Kagoshima, Japan 
Background: Thiazolidinediones are peroxisome proliferator-activated receptor-gamma 
agonists and are used to improve insulin resistance in type II diabetes mellitus. It is con- 
troversial whether thiazolidinediones promote or inhibit atherosclerosis in viva. The pur- 
pose of this study is to compare the effect of thiazolidinediones on atherosclerosis in 
apolipoprotein E (apoE)-deficient mice. Methods At 4 weeks of age, male apoE-defi- 
cient mice were weaned from mother and fed a powdered F-2 chow diet alone (control 
group, n=7) or F-2 chow diet with 0.2% troglitazone added (troglitazone group, n=7). with 
0.02% pioglitazone added (pioglitazone group, n=7), or with 0.002% rosiglitazone added 
(rosiglitazone group, n=7). The dose of drugs was determined by the clinical dosage of 
each drug. At 24 weeks of age, mice were sacrificed and atherosclerotic lesions in the 
aortic root were measured by a quantitative assay. Results There were no significant 
differences among 4 groups in body weight, total cholesterol. fasting blood sugar or 
HbAlc levels at 24 weeks. The atherosclerotic lesion of troglitazone group was signifi- 
cantly smaller than that of control group (control; 0.235iO.052 mm2 vs. troglitazone: 
0.170+0.057 mm’, p&05), in contrast, that of pioglitazone and rosiglitazone groups 
showed no significant difference compared to control group (pioglitazone; 0.260+0.081 
m&, rosiglitazone; 0.244*0.058 mni$ Troglitazona IS reported to be a radical-scaven- 
ger, because it has a similar structure wth vitamin E. Therefore, antioxidant actwity was 
determined by measuring plasma levels of isoprostane (8.epi prostaglandine F&x: 8epi 
PGF2a) with gas chromatography-mass spectrometry selected ion monitoring. The 
plasma 8-epi PGFZ& level of the trogl&szone group was significantly lower than those of 
other groups (troglitazone; 186+74 pglml vs. control; 353rll9, pioglitazone; 410*216, or 
rosiglitazone; 423~207. ~~0.05). Conclusion: Troglitazone with accessory antioxidant 
activity reduces isoprostane generation and the atherosclerosis in apoE-deficient mice, 
whereas pioglitazone and roslglitazone do not. 
1155-148 Differential Effects of Cyclooxygenase and Nitric Oxide 
Inhibition on Endothelium-Dependent Responses in 
Coronary Arteries From Juvenile and Adult Male Pigs 
Ritu Chatrath, Karen L. Ronningen, Peter LaBreche, Muthuvel Jayachandran, Margarita 
P. Bracamonte. Virginia M. Miller, Mayo Clinic Rochester, Rochester, MN 
Background: Experiments were designed to determine effects of puberty on endothe- 
lium-dependent responses I” coronary arteries of juvenile and adult males. 
Methods: Rings from right coronary artery with and without endothelium from 8 juvenile 
(2-3 mo: testosterone 67*17 mg/dL) and 8 adult (5-6 mo; testosterone 625+184 mg/dL) 
male pigs were suspended in organ chambers for measurement of isometric force. Dur- 
ing contractions to prostaglandin Fpa, cumulative concentration response curves to UK- 
14. 304 (a-adrenergic agonist) and bradykinin (BK) were obtained in the absence and 
presence of either indomethacin or indomethacm plus ~-monomethyl-L-arginine (L- 
NMMA) to inhibit cyclooxygenase and nitric oxide synthase, respectively. Blood was col- 
lected for measurement of nitric oxide (NO). 
Results: Plasma NO was significantly higher in juvenile compared to adult males 
(48.7k28.3 vs. 18.6*7.2 kmol/L, p<O.OOOl). UK-14, 304 caused similar concentration- 
dependent relaxations only in rings with endothelium from juvenile and adult pigs. With 
indomethacin, relaxations were significantly enhanced in arteries from adult pigs (EC, = 
7.9eO.27 -log mol/L), and reduced I” arteries from juvenile pigs (EC, = 6.7+0.37 -log 
mol/L) (p&023). L-NMMA significantly inhibited relaxations in arteries from both groups. 
Relaxations to BK also were similar in rings with endothelium from juvenile and adult 
pigs. In arteries from juvenile but not adult pigs, indomethacin caused a rightward shift of 
the dose response cwve (p=O.O8). Whereas, L-NMMA in the presence of indomethacin 
caused significant nghtward shift of dose-response curve (p=O.O3) in arteries from adult 
but not juvenile pigs. 
Conclusion: Endothelium-dependent responses are selectively modulated by cyclooxy- 
genase and nitric oxide inhibition in coronary artenes from male pigs. At immaturity, inhi- 
bition of cyclooxygenase reduces relaxations which is reversed with maturation. Nitric 
oxide is reduced with maturity and associated with relaxations to BK. Shifts from inhibi- 
tory tc contractile prostanolds and decreases in plasma NO may be related to production 
of testosterone 
1155-149 Short-Term Therapy With Gatifloxacin or Azithromycin 
Prevents the Acceleration of Atherosclerosis After 
Infection With Chlamydia Pneumoniae in a Rabbit 
Model but Does Not Eradicate the Organism From 
Plaque 
Heath U. Jones, Joseph B. Muhlestein. Tobin H. Llm. Jason Jensen, Robert R. Pearson, 
Beniamm D. Home. Mahtab Sohrevardl. John F. Carlauist. Jeffrev L. Anderson. LDS 
Hospital, Salt Lake City UT, Unwersity of Utah, Salt Lake City, UT 
Background: Chkmydia pneumoniae (Cpn) IS associated with atherosclerosis in human 
and animal studies, and short term (~3 months) antibiotic therapy has prevented Cpn- 
induced atherosclerosis in rabbits. However, short term antibiotic therapy has not dem- 
onstrated lasting clinical benefit in recent secondary prevention tnals. It is proposed that 
these poor long-term results may be due to inabIlIty of the antlbiotic to eradicate the 
organism. Both azthromycin (A) and gatifloxacln (G) are agents presently bemg tested 
for the secondary prevention of atherosclerosis. Whether either 1s able to eradicate Cpn 
from atherosclerotic plaque IS unknown. 
Methods: Forty-five rabbits received a 0.25% dietary supplement of cholesterol and were 
randomized 2:1 to Cpn infection or placebo and then randomized 1 :I :1 to A 30 mglkgl 
day X 1 week followed by 30 mg/kg twice weekly for 6 weeks, G 50 mg/kg/day for 7 
weeks, 01 placebo. One uninfected rabbit died spontaneously, and the rest were eutha- 
nized 3 months after initial infection. Blinded sections of the aorta were examined to cal- 
culate plaque percent area stenosis (PAS) (plaque area / total area within ,the internal 
elasbc lamina) The presence of Cpn within aortlc sections was evaluated by direct 
lmmunofluorescence (DIF) (Bartels). 
Results: PAS was greater for infected, untreated arteries (39*12%) than the other groups 
(non-infected = 21+12%; infected + A = 20+11%: infected + G = 22+14%, all p-values 
co.05 vs. infected-untreated). DIF was positive within the aortas of 0114 non-infected, 81 
10 infected/untreated, 400 infected/A, and 5/10 infected/G rabbits. 
Conclusion: Although a seven-week course of A or G significantly prevented Cpn- 
induced acceleration of atherosclerosis in the rabbit, neither was able to eradicate the 
organism by three months. This finding may help to explain the disappointing long-term 
results in recent clinical tnals. We propose that longer or different anti-mwobial therapy 
may be required to eradicate Cpn and provide lasting clinical benefit in the settmg of pri- 
mary or secondary prevention for atherosclerosis. 
1155-151 The Cardiac Peptide BNP Is Superior to ANP and the 
Renally Derived Peptide Urodilatin in Enhancing Renal 
Function in Overt Experimental Congestive Heart 
Failure 
Homq H. Chen, Alessandro Cataliotti, John A. Schirger, Gail Harty, John C. Burnett, Jr., 
Mayo Clinic and Foundation, Rochester, MN 
BACKGROUND: Recent studies have reported that improving renal function IS the most 
important predictor of suwival in congestive hearl failure (CHF). A hallmark of overt CHF 
is attenuated cGMP production to ANP with renal resistance. BNP is FDA approved for 
the management of acute CHF and is synthesized and released by cardiomyocytes. 
Urodilatin (Uro) is from the kidney and has been isolated from human urine with an amino 
acid (AA) sequence identical to ANP except for N-terminal extension of four AA residues. 
Studies have reported that exogenous Uro results III greater renal effects as compared to 
ANP but to date no comparison has been made with BNP nor ANP to BNP. METHODS: 
We determined the cardiorenal and humoral actions of equimolar infusion of (10 pmollkgl 
m(n) ANP (n=6), BNP (n=5) and Uro (n=6) in 3 separate group of dogs with rapid ventric- 
ular pacing induced overt CHF (240 bpm for 10 days)RESULTS: BNP resulted in 
increases in urinary sodium excretion (UNaV) (2.2* 0.7 to 164* 76 ~qlmln, ~~0.05) and 
glomerular filtration rate (GFR) (27+ 4 to 52* 11 ml/min, p=O.O5) which were greater as 
compared to Uro ( ~~0.05 BNP vs Uro), while ANP did not increase in either UNaV 01 
GFR. The increase in plasma cGMP (25+ 2 to 38+ 2 pmol/ml. p&O5 ) and urinary cGMP 
excretion with BNP (1618* 151 to 6124i 995 pmol/min, ~~0.05) wan? similar to Uro, 
however there was no significant change with ANP. Cardiac flllmg pressures were 
reduced similarly in all three groups. CONCLUSION: In this model of experimental overt 
CHF. infusion of BNP oroduced water increases III UNaV and GFR as compared to 
Uro, while ANP did not result in significant changes. These favorable renal effects were 
associated with increases in both clasma cGMP and urinarv cGMP excretion. which 
were similar with BNP and Uro, however were unchanged with ANP. Thts study demon- 
strates the superionty of BNP to Uro and ANP in enhancing renal function in severe 
experlmental CHF. These studies also support the conclusion that in CHF, renal resis- 
tance to natriuretic peptides in increasing rank order is ANP>Uro>BNP. These results 
may have clinical implications when considering the therapeutic efficacy of these pep- 
tides in the management of overt CHF. 
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1156-117 Prograf Decreases Plasma Cholesterol in Heart 
Transplant Recipients With Treated but Persisting Mild 
Dyslipidemia: The Canadian Multicenter Randomized 
Trial of Prograf Versus Neoral 
Michel White, on behalf of the Canadian Heart Transplantation Group. Montreal Heart 
Institute. Montreal, PC?, Canada 
Background: Despite optimal use of potent lipid-lowering agents, most heart transplant 
recipients exhibit persisting dyslipidemia not satisfying the current guidelines for high-risk 
patients. We have mitlated a Canadian mulbcenter prospective study of Neoral mainte- 
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nance versus conversion to Prograf immunoprophylaxis in stable heari transplant recipi- 
ents exhibiting persistent dyslipidemia despite optimal treatment with lipid-lowering 
agents. Methods: One hundred and twenty nine stable heart transplant recipients, aged 
56.7+10.1 years (mean&D) and 77.9i42.2 months post-op. were randomized to con- 
tinue on Neoral (n=64) or switch to Prograf (1x65). Comprehensive lipid profile was mea- 
sured at baseline (bsl)and after I, 3 and 6 months (6 mo). Hemostatic parameters 
(fibrinogen, factor VII. VIII. van Willebrand) and proinflammatory markers (hsCRP, 
homocysteine, slCAM, sVCAM, MCP-I, TPA. PAI-1) were measured at bsl and at 6 mo. 
Results: The Prograf-treated group exhibited a sigmficant greater decrease in total cho- 
lesterol [5.5ltl.l6 (bsl) versus 4.88tl.22 mmol/L. (6 mo): Prograf, versus 5.61+1.36 
(bsl): 5.38iO.87 mmol/L (6 mo): Neoral, p=O.O021]. The Prograf-group also yielded a sig- 
nificant decrease in LDL-cholesterol [3.10+0.8 (bsl) versus 2.72+0.88 mmollL (6 mo); 
p=O.OOS), and cholesterol/HDL ratio 14.73k1.48 (bsl) versus 4.15*1.36 (6 mo) p=O.O17]. 
The decrease in cholesterol was maximum at one month post-switch. For patients 
treated with Prograf. the change in plasma creatinine from baseline to month 6 [mean=- 
6.97t25.291 was significantly greater than for patients who remained on Neoral 
[mean=l.13+19.53] [p=O.O148]. Plasma glucose remains stable in the Prograf-treated 
patients [5.96*1.60 versus 6.01*1.87 mmol/L]. Conclusions: This large prospective con- 
version study showed that Prograf based immunoprophylaxis provides a significant 
decrease in total, LDL-cholesterol and CholesterotlHDL ratio as well as an improvement 
in renal function. These provide a rationale for the use of Prograf in cardiac transplant 
patients with treated but persisting dyslipidemia. 
1156-118 Elevated Soluble Tumor Necrosis Factor Receptor 
Levels in Nonobese Adults With the Atherogenic 
Dyslipoproteinemia 
Robert S. Rosenson, Christine C. Tangney, Daniel Levine, Thomas Parker, Bruce 
Gordon. Northwestern University. The Feinbero School of Medicine. Chicaoo. IL. The 
Rogosin Institute, New York, NY’ 
_ 
Background: Human adipocyte expression and protein levels of TNF-a and TNF recep- 
tor superfamily (TNFRSF) IB are positively correlated with body mass index (BMI) and 
insulin levels, and inversely correlated with adipose tissue lipoprotein lipase activity. In 
this study, we examine the relationships of select inflammatory mediators in the athero- 
genie dyslipoproteinemia (ADL) subjects and the effects of statin therapy on soluble 
TNFRSFs. 
Methods: 60 non-smoking, normoglycemic (HbAlc ~8%) subjects participating in a ran- 
domized 8 week trial comparing statin or placebo. ADL (TG >1.69 mmol/L, HDL-C cl.04 
mmoWL (40 mg/dL) in men and cl.30 mmol/L (50 mg/dL) in women, and/or small LDL 
(40.5 nm) was present in 42 subjects. 
Results: ADL subjects were younger (mean f SD; 49 + 8 YS 54 * 7 y, p=O.O19) and had 
higher levels of both TNF-a (7.9 f 18.1 vs 2.1 * 0.5 ng/mL, p=O.O13) and sTNFRSFlB 
(3.0 * 0.6 vs 2.7 f 0.5 ng/mL, p=O.OSS) compared to the 18 non-ADL subjects. After 
adjustment for age and gender, TNF-n (p=O.O47), sTNFRSFlA (p=O.O50) and 
sTNFRSFlB (p=O.O024) were predictive of ADL. There were no age and gander 
adjusted associations between IL-6 (p=O.O56) or hs-CRP (p=O.O93) and ADL status. Sta- 
tin therapy reduced TNF-a levels more in ADL subjects (7.9 * 18.1 to 6.2 * 11.9 ng/mL, 
p=O.O88) than in non-ADL subjects (2.1 + 0.5 ng/mL to 2.4 * 0.2 ng/mL, p=O.55), 
whereas sTNFRSFlA or sTNFRSFlB levels did not change. 
Conclustons: High levels of TNFa and TNFRSF IA and IB are markers of the proin- 
flammatory state in ADL. 
Predictors of Atherogenic Dyslipoprotenwnra: Multivanate Logistic Regression Analysis 
Overall Classification Overall P-Value 
Accuracy, % for Model 
Age + Gender 67.6 0.022 
Additional adjustment for: 
BMI 65.0 0.084 
TNFa 66.7 0.047 
sTNFRSF1 B 70.0 0.0024 
sTNFRSFlA 61.7 0.050 
IL-6 69.5 0.056 
hs-CRP 66.1 0.093 
sTNFRSFlA + sTNFRSFlB 74.6 0.0038 
sTNFRSF1 B + sTNFRSFlA + basal 66.7 0.047 
TNFa 
sTNFRSF1 B + sTNFRSFlA + IL-6 68.3 0.056 
sTNFRSF1 B + sTNFRSFlA + -hs-CRP 63.3 0.093 
sTNFRSFlA + sTNFRSFlB + TNFa + 66.7 0.037 
IL-6 + hs-CRP 
1156-119 Impact of Multiple Cardiovascular Disease Risk Factors 
on Brachial Artery Distensibility in Young Adults: The 
Bogalusa Heart Study 
Elaine M. Urbina Theda A. Foster, Sathanur R. Srinivasan, Jeffrey Tsai, Gerald S. 
Berenson. Tulane Health Sciences Center, New Orleans, LA, Pulse Metric, Inc., San 
Diego, CA 
Bsckground: Cardiovascular (CV) disease risk factors have been associated with global 
abnormalities in vascular function and structure, as quantified by increased arterial stiff- 
ness. Arterial distensibility decreases with age and the extent of arteriosclerosis. The 
subsequent rise in pulse pressure increases left ventricular work, thereby promoting left 
ventricular hypertrophy, a risk factor for CV morbidity. However, arterrosclerosis may 
affect segments of the vascular tree non-uniformly. The effect of CV risk factors on focal 
areas of the vascular tree is less well studied. Therefore, vascular function in the brachial 
artery and relationships with multiple CV disease risk factors were examined. Methods: 
Brachial artery distensibility was measured using pulse waveform analysis (DynaPulse 
2OOOA Pulse Metric, Inc.) (precision = 0.009543 mmHg-t; coefficrent of variation = 
14.7%; reliability = 0.58). CV risk factors evaluated included serum total and HDL choles- 
terols, serum triglycerides, glucose, body mass Index, and systolic blood pressure. Data 
were collected on 803 young adults from a community-based population (42% male, 
72% white, 19-37 years). Subjects were defined to have an abnormality in risk factor lev- 
els if they ranked in the highest quartile for this population (lowest quartile for HDL). 
Results: Approximately 58% of subjects had elevated levels in one or fewer risk factors, 
18% had clusters of two risk factors, and 24% had clusters of three or more risk factors. 
Results showed distensibility was significantly lower in blacks than in whrtes (0.063 vs. 
0.066 mmHg’ , p<O.M)5). An kwerse linear relationship was found between distensibility 
and the number of risk factors clustering in an individual (pcO.0001 for trend analysis). 
Conclusions: These observations show that clustering of risk factors is assocrated with 
decreased brachial artery distensibility in young adults and non-invasive measures of 
brachial artery funchon are useful in measuring sub-clinical vascular changes related to 
arteriosclerosis. 
1156-152 Acute Effects of Low-Density Lipoprotein Apheresis 
(HELP Procedure) on Cholesterol Oxidation Products 
and Novel Vasoactive Substances Urotensin and 
Relaxin 
Ewa Pulawski, Klaus P. Mellwg, Henning K. Schmidt, Thomas Brinkmann, Knut 
Kleesiek, Dieter Horstkotte, Heart Center North Rhine-Westphalia, Bad Oeynhausen, 
Germany 
Introduction: LDL apheresis according to HELP (APH) is used to treat severe hypercho- 
lesterolemia in patients (pts.) with coronary artery disease. It has been argued that either 
hyperchobsterobmia or extracorporeal treatment may enhance oxidative stress. Our 
study aimed to investigate the influence of a single APH on plasma concentrations (PC) 
of cholesterol oxidation products, urotensln and relaxin in pts. with heterozygous familiar 
hypercholesterolemia and advanced coronary artery disease enrolled in a chronic weekly 
APH. 
Methods: PC of oxidized LDL (oxLDL), superoxide dismutase (Cu/ZnSOD). relaxin and 
urotensin were determined by ELISA, malondialdehyde (MDA) by HPLC, the antioxida- 
tive serum capacity (ImAnOx) by photometric method. Samples of 12 pts. (6 F, 57 y *IO) 
were collected before (pre), immediately after (postl), and prior to the next APH (post2) 
after a week. 
Results: Pts. wth heterozygous familiar hypercholesterolemia showed higher PC of 
oxLDL than healthy controls (n=30). 11.4+6mU/I vs 7.7 mU/I (~~0.05) proportional to 
LDL-chol. (r=0.8, pcO.0601). APH reduced LDL-chol. and oxLDL by 52% and 45%, 
respectively. MDA declined by 30%. Cu/ZnSOD was not changed. Relaxin and uro- 
tensine decreased significantly. 
Conclusions: Single APH reduces cholesterol oxidation products as well as the vaso- 
constrictor urotensin without having an influence on plasma Cu/ZnSOD. The antioxida- 
tive serum capacity tends to decline after APH. 
Pre post 1 pre vs post 1 post 2 pre vs post 2 
OxLDL (mu/L) 11.4+6 6.25+3 p<o.o1 IO*3 n.s. 
MDA (umolll) 1.27iO.3 0.9+0.14 p<O.Ol 1.25kO.2 “.s 
ImAnOx (pmolll) 317*35 287+46 pzo.03 312*29 “.S. 
CU/ZnSOD (ng/ml) 75+36 71+27 n.s. 64220 no. 
Relaxin (pg/ml) 54+52 42244 p<o.o5 50*43 ns. 
Urotensin @g/ml) 40572983 23182656 p<O.OOOl 3636*1092 “.s. 
1156-153 Withdrawal of Statin Treatment Abrogates Its 
Cholesterol-Independent Beneficial Effects in Humans 
Wen-Ter Lai, Kun-Tai Lee, Chin-Sheng Chu, Hsueh-Wei Yen, Wen-Choi Voon, Chi-Hsin 
Hwang, Li-Yu Tsai, Sheng-Hsiung Sheu, Kaohsiung Medical University, Kaohsiung, 
Taiwan,ROC 
Background: Statins exert benificial effects on the vascular wall beyond cholesterol (C) 
lowering. Changes of these pleiotropic effects after discontinuation of statin remained 
unknown. 
Methods: Fourteen patients (8 F, 6 M, 59+17 years) with hypercholesterolemia were 
enrolled. The following 5 sets of serum liprd and 3 serum markers including vascular cell 
adhesion molecule-l(VCAM-I). 6-isoprostane(lS0) and trssue plasmrnogen activa- 
tor(tPA) for each patient were assessed:(l) at baseline; (2) 12 weeks after atovasta- 
tin(A)(lOmg/day); (3) at day I; (4) at day 2; (5) at day 3 after withdrawal of A. 
